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1. Introduction  
Gene-replacement gene therapy has been under development for a number of years. In spite 
of the large amount of research invested into developing gene therapy for the treatment of 
recessive genetic disorders only a limited number of patients world-wide have received the 
benefits. In addition, several high profile adverse events in gene therapy trials have lead to 
an increasing awareness of the challenges facing gene therapy treatments before they 
become established in the clinic. This has necessitated the development of novel advances in 
gene therapy vector design and delivery. This chapter will focus on the development of 
gene expression vectors incorporating native genomic regulatory elements that ensure 
transgene expression is physiologically relevant. Three main advances will be discussed 
here in detail; the use of whole genomic DNA loci to ensure physiologically-regulated 
transgene expression; development of viral vectors based on the herpes simplex virus type 1 
for delivery of whole genomic DNA loci; and the development of genomic mini-gene 
vectors that contain native regulatory regions for the physiologically-regulated expression 
of cDNA mini-genes.  
The principal aim of gene-replacement gene therapy is to complement the loss of function of 
an endogenous gene by supplying an exogenous ‘working’ copy in trans. The conventional 
approach to this is to supply a wild-type cDNA copy of the gene in a small vector in which 
transgene expression is controlled by a strong heterologous promoter, such as the 
immediate early promoter of cytomegalovirus (pCMV). The advantage of this approach is 
that the vectors are easy to use, have high levels of transgene expression, and fit easily into 
most viral delivery systems such as lentivirus and adenovirus. However, expression from 
these vectors is characteristically short-term and wide-spread with no tissue specificity or 
temporal regulation. One alternative to heterologous expression vectors for gene therapy is 
to utilise native genomic DNA regulatory elements to ensure gene expression that is both 
spatially and temporally regulated. A highly effective means of achieving gene expression 
that is physiologically-regulated is through the use of whole genomic loci which contain all 
introns, exons and regulatory regions in the correct genomic context. Expression from whole 
genomic loci has been proven to recapitulate endogenous expression. In the context of gene 
therapy, delivery of whole genomic loci using bacterial artificial chromosomes (BAC) has 
been shown to be an effective means of complementing gene deficiencies. Delivery of BAC 
vectors carrying complete loci encoding, for example, the genes for the human low density 
lipoprotein receptor (LDLR), the Friedreich's ataxia (FRDA) frataxin protein (FXN), 
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microtubule associated protein tau (MAPT) and hypoxanthine phosphoribosyltransferase 
(HPRT) effectively rescue gene deficiencies in vitro. It has also been shown that the 
complementation of gene deficiency is responsive to changes in the cellular milieu, an 
important point for conditions where gene expression is controlled by cellular signalling 
pathways and where over-expression of the gene is toxic.  
Historically, BAC vectors have been discounted for gene therapy purposes as there was no 
viral delivery system with the transgene capacity for a whole genomic locus which may be 
≥100 kb. Recently, viral vectors based on the herpes simplex virus type (HSV-1) amplicons 
have been developed and shown to have a transgene capacity of over 100 kb and a broad 
cell tropism making them an attractive means of delivering large transgenes for the 
purposes of gene therapy. Currently HSV-1 amplicons have been used in a number of gene 
complementation studies which will be reviewed in detail here.  
Recent work in our laboratory has adapted the genomic locus approach for the treatment of 
familial hypercholesterolaemia (FH). FH is a condition caused by mutations in the LDLR 
gene and represents a unique challenge in gene therapy. Over-expression of the LDL 
receptor leads to a toxic accumulation of intracellular cholesterol. It is therefore essential 
that LDLR transgene expression is appropriately regulated. We have generated gene 
expression vectors in which expression of the LDLR cDNA was controlled by 10 kb of 
genomic DNA encompassing key regulatory regions in the LDLR genomic DNA promoter. 
These regulatory regions sense the levels of intracellular cholesterol. When cholesterol levels 
in the cell are high, LDLR expression is low; when the cholesterol stores become depleted, 
expression of the LDL receptor is high. Delivery of the LDLR mini-gene expression vectors 
in vitro and in vivo lead to efficient and prolonged LDLR gene expression in vivo that is 
sensitive to changes in cellular cholesterol and resulted in a decrease in circulating 
cholesterol in receptor deficient mice.   
2. Physiologically-relevant gene expression vectors: use of a complete 
genomic locus 
The central aim of gene-replacement gene therapy is to complement the loss of function of 
an endogenous gene by supplying a working copy of that gene in trans. Classically this was 
achieved using cDNA coding for the endogenous gene under the expression control of 
constitutively active exogenous promoters such as the immediate early promoter from the 
cytomegalovirus (pCMV). In general transgene expression levels from these vectors are 
characteristically high and therefore therapeutic effect is seen in some conditions. Clinical 
trials have demonstrated that these vectors are effective in ameliorating the symptoms of 
conditions such as haemophilia (Manno et al. 2006) and several severe combined 
immunodeficiencies (SCID) such as X-linked SCID (Cavazzana-Calvo et al. 2000), adenosine 
deaminase deficiency (Aiuti et al. 2009) and chronic granulomatous disease (Ott et al. 2006). 
The SCID trials also demonstrated that delivery of transgenes in the context of small cDNA 
vectors with no native expression control did have a number of issues including cell 
transformation. 
2.1 Complete genomic locus ensures gene expression in the correct genomic context 
There are several issues which may confound the use of cDNA expression cassettes to 
complement the loss of function of an endogenous gene: aberrant spatial expression 
dynamics resulting in gene expression in ‘off-target’ cells; aberrant temporal dynamics 
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resulting in continuous expression of a transgene with possible cytotoxic consequences; 
transgene over-expression at supra-physiological levels; and, the inability to produce 
multiple splice variants. 
Transgenic mice offer an interesting insight into the benefits of using native genomic loci 
over cDNA expression systems to investigate the function of genes. For some genes it is 
essential that they are expressed in the correct spatial, developmental and temporal context 
to ensure functionality. The ǃ-globin gene cluster is an excellent example of this. This 
genomic locus consists of five separate genes (5’-ǆ-GǄ-AǄ-ǅ-ǃ-3’) that are expressed at 
different developmental stages (Huang et al. 2000). The Ǆ genes are expressed in foetal 
erythroid tissues while the ǅ and ǃ are expressed in adult haematopoietic cells of the 
erythroid lineage. The expression of these genes in under the control of a region called the 
locus control region (Huang, Liu et al. 2000). In mice expressing the ǃ-globin from a cDNA 
expression plasmid without the locus control region, low levels of protein are detected with 
no tissue-specificity (Magram et al. 1985; May et al. 2000; Vadolas et al. 2005). The use of the 
entire genomic locus of the ǃ-globin gene cluster which included the locus control regions 
resulted in spatial and temporal expression profiles that mimicked the native profile (Porcu 
et al. 1997; Vadolas, Wardan et al. 2005).  
Further examples of the advantages of using the complete genomic locus comes from mice 
lacking either the frataxin (Fxn) gene (Cossee et al. 2000; Miranda et al. 2002) or the cystic 
fibrosis transmembrane conductance regulator (Cftr) gene (Zhou et al. 1994; Manson et al. 
1997), mouse models of Friedrich’s ataxia and cystic fibrosis, respectively. Mice lacking 
frataxin die at embryonic day six and crossing heterozygous knock-out mice with mice 
expressing the full genomic locus of the human FXN gene from a bacterial artificial 
chromosome (BAC) rescues the phenotype and expression patterns of mRNA and protein 
was physiological (Sarsero et al. 2004). Transgenic mice lacking the endogenous Cftr gene 
but expressing the full 200 kb of the human CFTR gene in a yeast artificial chromosome 
(YAC) show correct expression of CFTR protein in the appropriate spatial and temporal 
context (Manson, Trezise et al. 1997). 
Other examples include comparisons between mice expressing the amyloid precursor 
protein (APP) as either a cDNA construct or as a complete locus within a YAC. The APP 
gene is involved with the development of Alzheimer’s disease. It is a complex genomic locus 
comprising 18 exons that are alternatively spliced to give rise to four distinct transcripts 
(Hsiao et al. 1996). Mice expressing the APP cDNA vector do not express APP protein in the 
correct genomic context limiting the relevance of biological information obtained from these 
animals (Lamb 1995; Lamb et al. 1997). Mice expressing APP from the YAC construct 
displayed physiologically-relevant APP protein expression making them a far superior tool 
for the study of how APP might contribute to the development of Alzheimer’s disease 
(Lamb, Call et al. 1997). 
The advantages of using BAC plasmids to generate transgenic mice is now widely accepted. 
BAC transgenics have been shown, for example, to rescue knockout phenotypes in mice 
lacking the Pkd1 gene involved in polycystic kidney disease (Pritchard et al. 2000) and mice 
lacking ǃ-globin genes (Vadolas et al. 2002; Jamsai et al. 2005; Vadolas, Wardan et al. 2005; 
Jamsai et al. 2006). BACs have also been useful in investigating novel genomic expression 
control regions. A negative regulatory region in the Wilson’s disease gene was characterised 
using BAC plasmids (Bochukova et al. 2003). BACs were also used to characterise the locus 
control regions responsible for the differential expression of Myf5 in skeletal muscle 
(Carvajal et al. 2001; Zammit et al. 2004). In addition to this, insertion of reporter genes into 
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BAC plasmids has enabled the understanding of spatial and temporal expression dynamics 
of many genes such as Nkx2-5 (Chi et al. 2003). Recently BAC transgenesis has been used in 
studies of immunomodulation (Kulik et al. 2011), blood vessel development (Ishitobi et al. 
2010) and in generating mouse models of Parkinson’s disease that more closely recapitulate 
deficits in the human disease (Li et al. 2009). These studies represent a small sub-section of 
the work being performed using whole genomic loci to better understand gene function. 
They demonstrate that the use of native regulatory regions can yield more biologically-
relevant data than over-expression studies. This is important in the generation of mouse 
models of disease and also in the development of therapeutic protocols to treat genetic 
disease.  
2.2 Complete genomic locus for therapy 
Transgenic animals offer extensive evidence that the use of cDNA expression vectors often 
does not result in physiologically-relevant expression patterns. In terms of gene therapy the 
use of these cDNA vectors may not be appropriate for diseases where the correct 
physiological expression of the transgene is vital for therapeutic effect and to protect cells 
from ectopic or cytotoxic over-expression, where proteins expressed with no control result 
in pathological changes in the transduced cell.  
The use of a complete genomic DNA region in the design of gene therapy vectors is still a 
relatively new field. Manipulation and use of such large pieces of DNA can be challenging. 
Success has been seen however with a range of genes using a number of different techniques 
to isolate and deliver the locus. In vitro studies demonstrated that it was possible to achieve 
gene expression following non-viral BAC plasmid delivery. The gene involved in Lesh-
Nyan syndrome, hypoxanthine phosphoriribosyltransferase (HPRT) was delivered to HPRT 
deficient fibroblasts and resulted in sustained physiological levels of HPRT (Wade-Martins 
et al. 2000). Lipofection and an integrin targeting peptide were used to deliver a 143 kb BAC 
encompassing the locus of Nijmegen breakage syndrome gene (NBS1) resulting in 
expression of the NBS1 gene product, nibrin (White et al. 2003). BACs have also been 
generated that contain the CFTR locus (Kotzamanis et al. 2009) delivery of which to CMT-93 
cells resulted in mRNA expression that was correctly spliced (Kotzamanis, Abdulrazzak et 
al. 2009).   
In vivo non-viral delivery of plasmids containing large genomic DNA inserts has been 
achieved in two studies. In the first study hydrodynamic tail vein injection or lipofection 
was used to successfully deliver plasmids containing 150 kb of non-gene specific DNA 
(Magin-Lachmann et al. 2004). We have also demonstrated efficient delivery of a 135 kb 
genomic insert containing the full human low density lipoprotein receptor (LDLR) genomic 
locus for the treatment of Familial Hypercholesterolaemia (FH). We showed that up to 4 
months following hydrodynamic tail vein injection, human LDLR protein was detectible in 
the livers of recipient mice (Hibbitt et al. 2007).  
Alternatives to BAC plasmids for delivery of large genomic inserts are also being 
investigated. Human artificial chromosomes (HACs) for example offer advantages over the 
bacterial counterparts. HAC vectors are able to replicate and segregate without integration 
into the host-cell chromosomes and are capable of carrying very large amounts of DNA. 
HACs have been shown to be an effective means of generating transgenic mice (Suzuki 
2006).  They have also been used to express HPRT (Moralli et al. 2006) and CFTR complete 
genes (Rocchi et al. 2010).  In addition a HAC containing the entire 2.4 Mb genomic locus of 
the human dytrophin gene was used to stably maintain expression of human dystrophin in 
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mouse embryonic stem cells (Hoyshiya 2009) without any integration into the host cell 
chromosomes. These cells were used to generate chimeric mice analysis of which showed 
correct tissue-specific dystrophin expression. As the HACs are stable they could be useful in 
cell therapies in the future.  
Viral vectors have also been developed to achieve infectious delivery of large genomic 
sequences. A gutless adenovirus with a transgene capacity of 36 kb was used to deliver the 
whole locus of the human ǂ1 antitrypsin gene (SERPINA1) to mice (Schiedner et al. 1998). 
Vectors based on the Epstein Barr virus have also been used to deliver 120 kb of genomic 
DNA to cells of lymphoblast and B-cell lineage (White et al. 2002). Other viral systems have 
been under investigation, such as CMV which has a very large transgene capacity of around 
210 kb and a strong haematopoietic cell tropism (Borst and Messerle 2000; Borst and 
Messerle 2003). However, the best characterised is amplicon vectors based on Herpes 
Simplex 1 (HSV-1). 
2.3 Infectious delivery of a complete genomic locus – HSV-1 amplicons 
The large size of a compete genomic locus precludes their use with most viral vector 
systems which typically have a transgene capacity of less than 20 kb. Vectors based on the 
herpes virus family however have a much larger transgene capacity. HSV-1 in particular is 
well described and widely used. Wild-type HSV-1 infects mucosa and establishes a latent 
phase in sensory neurons. HSV-1 infection produces cold sores in symptomatic infected 
individuals and 90% of the population has circulating antibodies (Corey and Spear 1986; 
Bowers et al. 2003). The HSV-1 genome consists of 152 kb of double stranded DNA. Of this 
only two non-coding regions are required for the packaging of DNA plasmids into HSV-1 
virions (Spaete and Frenkel 1982; Spaete and Frenkel 1985).  Inclusion of these two 
packaging signals, the OriS and pac, into DNA plasmids will promote their packaging into 
HSV-1 virions in the presence of the HSV-1 genome in trans. Plasmids are packaged head to 
tail in concatemers up to 150 kb. The average size of a human genomic locus is around 40 kb 
and the 150 kb capacity of HSV-1 amplicons potentially allows delivery of up to 90% of 
genomic loci as infectious particles, making the vector a highly versatile viral packaging 
system (Senior and Wade-Martins 2005; Hibbitt and Wade-Martins 2006).  
HSV-1 amplicons are capable of infecting dividing and non-dividing cells including, but not 
limited to; neurons, such as those of the dorsal root ganglion (Marsh et al. 2000), thalamus 
(Costantini et al. 1999), cortex (Agudo et al. 2002), hippocampus (Adrover et al. 2003), glial 
cells (Marsh, Dekaban et al. 2000), gliomas (Shah et al. 2004), skeletal muscle (Wang et al. 
2000; Wang et al. 2002) and osteoblasts (Xing et al. 2004). HSV-1 amplicons also retain their 
ability for retrograde transport in neuronal axons allowing for the possibility of peripheral 
delivery for centrally located targets. For example inoculation of the foot pad in diabetic rats 
with HSV-1 amplicons expressing nerve growth factor (NGF) resulted in NGF expression in 
the dorsal root ganglion and protected against diabetes associated peripheral neuropathy 
(Goss et al. 2002). 
One of the key concerns with any viral vector system is safety. HSV-1 amplicons are non-
integrating viruses which thus avoids issues of cell transformation by insertional 
mutagenesis. The packaging of OriS and pac containing plasmids into HSV-1 amplicons 
requires the presence of the HSV-1 genome in trans. To improve vector safety helper virus-
free HSV-1 amplicon packaging systems have been developed. The supply of the HSV-1 
genome in trans has been achieved by the use of BAC plasmids encompassing the full 
genome and lacking the packaging signal (Saeki et al. 1998; Stavropoulos and Strathdee 
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1998). Further safety mechanisms were then added to the system. One recent packaging 
BAC now widely used has both the packaging signal (pac) and the essential gene, ICP27, 
deleted, and is also oversized to preclude its inclusion into HSV-1 virions (Saeki et al. 2003). 
It has also been demonstrated that this packaging system is an efficient means of generating 
infectious BAC (iBAC) particles that have been successfully used for gene expression in vivo 
and in vitro. Overall, helper virus-free packaging systems for HSV-1 amplicons result in 
vector stocks with a much reduced immune-response in vivo (Olschowka et al. 2003).  
 
 
Fig. 1. Packaging of HSV-1 amplicons. 
Schematic showing packaging of OriS and pac containing plasmids into HSV-1 virions. A) 
AniBAC plasmid containing the gene of interst (GOI) is packaged using packaging virus to 
supply  the HSV-1 genome in trans. This results in viral stocks that contain virions only 
carrying the iBAC GOI plasmid and wild-type-like virus. B) An improved packaging system 
using two plasmids in place of the wild-type-like virus. An oversized, ICP27 deleted BAC 
plasmid and a small plasmid that contains ICP27. This results in viral stocks that only 
contain virions with GOI containing iBAC. 
HSV-1 delivers DNA to the cell as an extrachromosomal element and hybrid vectors have 
been designed to promote persistence of episomal vector DNA (Figure 2). The best 
described of these is the HSV-1/EBV hybrid vectors. The inclusion of the EBV latent origin 
of replication OriP and the EBV nuclear antigen (EBNA-1) promotes replication and 
segregation of DNA during cell division (Wang and Vos 1996; Wade-Martins et al. 2001; 
Wade-Martins et al. 2003; Muller et al. 2005). Mammalian-based systems have also been 
investigated. The inclusion of scaffold matrix attachment regions (SMARs) to an iBAC 
containing the human LDLR gene resulted in the establishment of stable, episomal LDLR 
expression in cell lines (Lufino et al. 2007). Successful delivery and establishment of HACs 
has been shown in cells transduced with iBAC vectors carrying alpha satellite DNA inserts 
(Moralli, Simpson et al. 2006).  
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A BAC plasmid containing complete genomic locus can be retrofitted using cre-LoxP recombination 
with small plasmids containing elements essential for extrachromosomal maintance of delivered 
plasmids. Suggested in this figure is the incorpation of a CMV-green fluorescence protein (CMVGFP) 
reporter gene cassette to allow for assessment of delivery. The HSV-1 packaging signals (pac and oriS)  
and retention elements. ; 1) Contains the episomal  retention elements from the Epstein Barr virus 
(EBNA-1 and oriP), 2) contains the S/MAR retention elements, 3) Alpha satelite DNA promotes the 
generation of human artificial chromosomes following delivery. 
Fig. 2. Extrachromosomal retention elements.  
The use of iBAC vectors in gene therapy is still evolving and a number of studies have 
demonstrated that these vectors are capable of efficient delivery and genetic 
complementation. Recent work has used the delivery and expression of the complete 
genomic of two genes key to the development of Alzheimer’s disease and Parkinson’s 
disease, microtubule associated protein tau (MAPT) and alpha synuclein (SNCA) to study 
gene function. Amplicon iBAC vectors carrying the 143 kb MAPT locus or the 135 kb SNCA 
locus were used to infect cellular models of neurodegeneration (Peruzzi et al. 2009). 
Expression of MAPT and SNCA in cells infected with the iBAC vectors was similar to 
endogenous human levels. It was found by comparing transgene expression in primary 
neuronal and glial cultures that expression from the MAPT locus was strictly regulated by 
developmental time-point and cell type. Multiple transcripts were observed which 
mimicked the expression pattern seen in humans. Infection of MAPT-deficient neurons in 
culture with the MAPT iBAC vector rescued the cellular phenotype, restoring the normal 
response to Aǃ-peptide (Peruzzi, Lawler et al. 2009). This delivery system provides an 
effective means of investigating neurodegeneration in cell models. 
Success had already been seen previously using iBAC vectors coding for the HPRT (Wade-
Martins, Smith et al. 2001) as described in Section 2.2 or bone morphogenic protein 2 (BMP2) 
(Xing, Baylink et al. 2004) loci. The role of BMP2 in osteoblast formation was investigated 
using iBAC delivery of the complete BMP2 locus (Xing, Baylink et al. 2004). BMP2 has been 
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implicated in the differentiation of osteoblasts by altering alkaline phosphatase activity in 
precursor cells (Thies et al. 1992). When the iBAC-BMP2 vector was used to infect a 
preosteoblast cell line differentiation was observed consistent with appropriate BMP2 
expression (Xing, Baylink et al. 2004).  
Small cDNA-based vectors are not suitable to express loci which undergo complex splicing, 
such as the MAPT locus discussed above. Another example is the human CDKN2 genomic 
locus, an especially complex region. Expression from the CDKN2 locus results in five 
different genes from only six exons (Sharpless and DePinho 1999). Two of the genes p16INK4a 
and p14ARF are particularly complex. Two separate promoter regions control expression of 
each gene. Separate first exons are spliced with second and third exons which are shared 
between the two transcripts (Sharpless and DePinho 1999). Both of these genes are involved 
in cell cycle control. They are being investigated as potential targets for cancer gene therapy. 
The 132 kb CDKN2 locus was delivered as a iBAC vector to CDKN2 knockout glioma cells. 
Cells transduced with the iBAC vector has physiological levels of expression and correct 
splicing of three gene products of the CDKN2 locus, p15, p16INK4a and p14ARF (Inoue et al. 
2004). Cells also displayed a phenotype of reduced growth consistent with expression of cell 
cycle arrest genes (Inoue, Moghaddam et al. 2004).  
HSV-1 amplicons have been used to deliver the complete genomic locus of the LDLR gene to 
cell models of FH (Wade-Martins, Saeki et al. 2003; Lufino et al. 2007; Lufino, Manservigi et 
al. 2007). It was shown that delivery of the LDLR locus as an iBAC to Ldlr deficient CHO 
cells and FH patient fibroblasts lead to attenuation of the cellular phenotype as seen by 
normalisation of uptake and internalisation of LDL (Wade-Martins, Saeki et al. 2003; Lufino, 
Manservigi et al. 2007). Long-term expression was achieved by the use of the EBV episomal 
retention elements (Wade-Martins, Saeki et al. 2003) or scaffold matrix attached regions 
(Lufino, Manservigi et al. 2007). Both episomal retention systems promoted efficient 
establishment of the LDLR locus as a extrachromosomal element (Wade-Martins, Saeki et al. 
2003; Lufino, Manservigi et al. 2007). Expression from this locus was down-regulated by 
sterol treatment through interaction with response elements in the promoter region (Wade-
Martins, Saeki et al. 2003; Lufino, Manservigi et al. 2007).  
The first example of in vivo infectious delivery of a whole genomic locus using the iBAC 
delivery system was recently described (Gimenez-Cassina et al. 2011). The entire 135 kb 
FXN gene was delivered as an iBAC directly to mouse cerebellum using intracranial 
injection. Analysis of expression of the LacZ reporter gene expressed from within the FXN 
locus showed large numbers of transduced cells in the cerebellum up to 75 days post-
injection. This was also compared to reporter gene expression from the viral HSV-1 IE4/5 
promoter which was short-lived in vivo from the same vector. This work is an elegant 
demonstration of the potential of BAC plasmid delivery in vivo to result in high-level 
sustained transgene expression. 
The LDLR expression and FXN iBAC delivery studies represent an interesting proof of 
principle in the use of complete genomic regions to treat genetic disease via gene therapy. 
Delivery of the whole genomic locus is an elegant way to provide the therapeutic gene in its 
correct genomic context, ensuring that complementation can be physiologically-relevant, 
cell-specific and temporally-regulated. This has the potential effect of decreasing 
genotoxicity and improving the safety and efficacy of gene therapy vectors. However, the 
use of large genomic inserts can be technically challenging. Work is underway to develop 
gene expression vectors that combine the gene-regulation of a large insert with the 
convenience of a small mini-gene vector. 
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4. Physiologically-relevant gene expression vectors: use of native regulatory 
regions 
Whole genomic loci represent an excellent means of ensuring physiologically-relevant 
expression in target cells. However, the large size of BAC plasmids precludes their use in all 
but a few viral vector systems. Although, non-viral systems such as hydrodynamic tail vein 
injection offer excellent means of delivery to target certain tissues, for many applications 
BAC-sized plasmids may not be practical. Many studies have attempted to combine the 
advantages of cDNA vectors (small size, high transduction or transfection efficiency, and 
high levels of protein expression) with an advantage of a whole genomic locus, being 
regulated physiologically-relevant expression. Depending on the gene of interest it may be 
necessary only to ensure expression of the transgene is restricted to a particular cell type; 
alternatively, it may be necessary to ensure transgene expression also tracks changes in cell 
physiology to ensure therapeutic and not pathologic transgene expression. 
There has been extensive research into targeting gene expression to desired tissues using 
transcriptional restriction. Such work uses well-characterised promoters and enhancer 
regions that limit transgene expression to certain desired cell types where they are active. 
Liver-directed gene expression for example has been achieved using the promoter regions 
from either the albumin (Follenzi et al. 2002) or ǂ1 antitrypsin genes (Le et al. 1997) to target 
expression of clotting factors to the liver to treat the haemophilia family of diseases. 
Targeting gene expression to cells in vascular wall is possible using endothelial cell 
restricted expression through the use of promoter such as VE-cadherin or VEGFR-1 (Quinn 
et al. 2000; Nicklin et al. 2001). Vascular smooth muscle specific expression has been 
achieved using promoters like the SM22 promoter (Imai et al. 2001) and was successfully 
used to target expression of heme oxygenase 1 to the vascular endothelium.  
For some diseases it is not enough to limit expression to cell type. The temporal dynamics of 
gene expression is also important. One novel way of achieving physiological expression 
using small cDNA vectors is to generate a genomic mini-gene construct that uses native 
gene expression elements with a cDNA transgene. Wiskott-Aldrich syndrome (WAS) is an 
excellent example of the need for native regulatory elements to ensure correct expression 
dynamics. WAS is an X-linked recessive disease caused by mutations in the WAS protein 
gene (WAS) and defined by thrombocytopenia. WAS is expressed in haematopoietic cells at 
different concentrations depending on the cell type (Toscano et al. 2008). Over-expression in 
non-haematopoietic cells has been shown to be cytotoxic (Toscano, Frecha et al. 2008). 
Lentiviral delivery of WAS cDNA vectors where expression is governed by different 
fragments of the WAS gene promoter ranging from 500 bp to 1600 bp has demonstrated 
restricted expression of WASP in haematopoietic cells (Dupre et al. 2004; Martin et al. 2005; 
Leuci et al. 2009). These vectors were also able to correct the genetic defect in Was knockout 
mice and transduce haematopoietic cells from WAS patients. However, these relatively 
small promoter fragments were unable to achieve complete physiological regulation and 
some target cell types did not exhibit correct transgene expression profiles (Frecha et al. 
2008). This may be because the promoter fragment was too small to contain all necessary 
machinery for all target cells.  
One example in which clinical success has been seen with a vector containing native 
regulatory elements is in treatment of Leber’s congenital amaurosis, a group of recessive 
congenital rod-cone dystrophies. Mutations in a retinal pigment epithelium specific gene 
called RPE65 causes impaired vision from birth that degenerates to complete blindness later 
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in life.  An adeno-associated virus was constructed that contained the RPE65 cDNA under 
the expression control of 1600 bp human RPE65 promoter (Le Meur et al. 2007). The use of 
the native promoter region of the RPE65 gene effectively targeted expression to the retinal 
epithelium. This was shown to be effective at improving vision in a naturally occurring 
animal model; the Swedish Briard dog. This vector is now in clinical trials to treat this 
condition in humans (Bainbridge et al. 2008).  
These two examples use only a minimal promoter region, which may be appropriate for 
those genes where regulatory elements are located in a small region proximal to the start of 
the coding region. However, as was seen in the WAS example, a larger portion of genomic 
DNA may be necessary for full physiological regulation. In our laboratory we have 
investigated the use of a 10 kb piece of genomic DNA to ensure fully physiological 
expression of the low density lipoprotein receptor gene (LDLR) for functional 
complementation in vitro and in vivo for the treatment of familial hypercholesterolaemia 
(FH). FH is caused by mutations in the LDL receptor which binds and internalises LDL 
cholesterol in response to low intracellular cholesterol levels. Gene therapy for FH been 
under investigation for a number of years with many published investigations reporting 
lowering of plasma cholesterol following delivery of cDNA vectors where expression is 
driven by heterologous promoters and delivery is achieved by virus-mediated liver-directed 
transduction with retrovirus (Miyanohara et al. 1988; Wilson et al. 1988; Chowdhury et al. 
1991; Grossman et al. 1995; Kankkonen et al. 2004), adenovirus (Ishibashi et al. 1993; 
Kozarsky et al. 1994; Li et al. 1995; Kozarsky et al. 1996; Nomura et al. 2004; Jacobs et al. 
2008; Van Craeyveld et al. 2011) and adeno-associated virus (Lebherz et al. 2004; Kassim et 
al. 2010). These previous studies included a clinical trial (Grossman, Rader et al. 1995) that 
showed no evidence of long-term therapeutic effect.  
FH represents a significant challenge for gene therapy due to the regulation of LDLR. There 
are three issues that need to be overcome by a therapeutic protocol. Firstly, cholesterol 
biosynthesis in the liver is constitutive. This means any gene therapy protocol needs to 
supply an agent that is not only capable of clearing cholesterol already present in the serum, 
it needs to clear all future cholesterol that will be synthesised by the liver. This puts huge 
demands on the transduced cells. The second issue is that the LDLR locus is tightly 
regulated by a negative feedback system. Expression from the LDLR genomic locus is 
controlled by levels of intracellular cholesterol. When intracellular levels of cholesterol fall 
LDLR expression is triggered by the binding of sterol response element binding proteins 
(SREBP) to the sterol response elements in the promoter region (Sudhof et al. 1987; Briggs et 
al. 1993; Horton et al. 2002). This drives expression of the LDL receptor which binds and 
internalises LDL particles from the circulation. As cellular cholesterol stores become replete 
the SREBP become less active and expression from the LDLR locus is repressed. There is 
evidence that suggests hepatocytes are only metabolically able to deal with a certain amount 
of cholesterol influx. Delivery of cDNA vectors with strong viral promoters driving LDLR 
expression into cells, and animals, using adenovirus results in immediate, dramatic 
lowering of cholesterol. The initial lowering of cholesterol is slowly eroded over time as 
intracellular cytotoxic accumulation of cholesterol leads to apoptotic cell death and loss of 
the transduced population of cells.  The third confounding factor is the physiological 
expression itself. It is apparent that physiologically-relevant expression of the LDLR is 
important for the function of the hepatocytes and the nature of the expression plasmid may 
limit its ability to clear large amounts of cholesterol from the blood. As the cholesterol stores 
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in transduced cells become replete the expression of the LDLR transgene will be repressed 
effectively ‘switching off’ that particular cell’s cholesterol processing ability, this could 
reduce the therapeutic effectiveness of physiological vectors.   
We have previously shown that an iBAC vector containing the 135 kb LDLR genomic locus 
encompassing all 18 exons, intervening introns, sterol response elements and other 
regulatory elements all in the correct genomic context was capable of rescuing the genetic 
defect in cell models of FH (Wade-Martins, Saeki et al. 2003; Lufino, Manservigi et al. 2007). 
When we moved the focus of the work into animal models of FH we found that non-viral 
gene transfer via hydrodynamic tail vein injection to be an efficient means of vector 
delivery. Delivery of the LDLR BAC using hydrodynamic tail vein injection resulted in long-
term expression of human LDLR in the liver over the full four month course of the 
experiment (Hibbitt, Harbottle et al. 2007). However, the level of hepatocyte transduction 
was insufficient to result in therapeutic lowering of cholesterol.  
The challenge was to maintain physiologically-regulated expression while improving 
transfection efficiency using hydrodynamic tail vein injection. We built genomic DNA mini-
gene vectors that contained 10 kb of genomic DNA encompassing the full genomic DNA 
promoter of the human LDLR gene (Hibbitt et al. 2010). This consisted of the 5′ untranslated 
region, three sterol response elements, the transcription initiation sequence and eight kb 
upstream of genomic DNA that may contain as yet undescribed enhancer elements (Figure 
3a). This genomic DNA promoter region was used to drive the cDNA of either the luciferase 
or human LDLR genes. We have shown in vitro that the 10 kb LDLR promoter provides 
stable, long-term, physiological expression and provides functional complementation in cell 
culture in Ldlr deficient CHO cells and FH patient fibroblasts (Figure 3b). Physiological 
LDLR promoter induction was demonstrated using either luciferase expression, or specific 
LDL binding and internalisation assays in the presence of modifiers of receptor expression, 
sterols or statins. Statins are specific inhibitors of the de novo cholesterol synthesis pathway. 
They act on the LDL receptor by decreasing the amount of cholesterol in the cell thereby up-
regulating expression from the LDLR promoter. Incubation of cells with statins lead to a 
five-fold up-regulation of expression from the 10 kb promoter element. Sterols down-
regulate LDL receptor expression through association with sterol response elements in the 
LDLR promoter region. Incubation with sterols lead to a 50% down-regulation of expression 
from the 10 kb promoter element.  
Liver-directed delivery of LDLR mini-gene vectors in vivo using hydrodynamic tail vein 
injection resulted in expression from the LDLR promoter element that was sensitive to drug 
administration in vivo. Pravastatin administration resulted in a five-fold increase in 
luciferase expression five days after delivery (Figure 3c). The inclusion of EBV episomal 
retention elements ensured long-term expression up to 240 cell cycles in vitro and 9 months 
in vivo (Hibbitt, McNeil et al. 2010).  
This work describes the successful combination of genomic DNA regulatory elements with a 
mini-gene cDNA vector. Expression from this vector is physiologically-regulated by 
intracellular cholesterol levels. Delivery of the smaller-sized mini-gene vector is more 
efficient than with the full BAC and highlights the possibility of combining gene 
replacement gene therapy with traditional medical treatments. Combining gene delivery 
with treatment that will reduce the amount of cholesterol being synthesised by the liver 
could increase the power of the gene delivery ensuring efficient binding and internalisation 
of LDL to reduce plasma cholesterol levels. We have demonstrated in vivo that treatment 
with statin drugs increases the activity of the LDLR promoter. We have also investigated the 
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feasibility of using a more targeted approach. Statins work by inhibiting the conversion of 
HMG CoA to mevalonate by 3-hydroxy-3-methylglutaryl Coenzyme A reductase 
(HMGCR), the rate limiting step in cholesterol synthesis inhibitors. We have investigated 
whether knock-down of HMGCR might have a more specific effect leading to a greater 
reduction in cholesterol synthesis and therefore greater induction of LDLR. We have 
demonstrated that treatment with HMGCR-specific small-interferring RNAs and synthetic 
microRNAs leads to a ten-fold induction of the LDLR promoter in vitro and in vivo which 
resulted in a greater reduction in circulating LDL cholesterol in Ldlr knockout mice (Hibbitt 
et al. Accepted).  
 
 
Generation of LDLR genomic mini-gene vectors. A) A 10kb Icece of genomic DNA encompassing the 
LDLR promoter the promoter region (UTR) and 8kb upstream of genomic DNA was cloned into vectors 
containing the cDNA of either luciferase or LDLR.  B) Following delivery of LDLR cDNA containing 
vectors to patient fibroblasts binding and internalisation of LDL was observed. Increased binding was 
seen after cells were treated with statins. Decreased binding was observed with cells treated with 
sterols. Cells transduced with a control vector that did not contain the LDLR expression cassette 
showed no binding and internalisation of LDL. C) Animals injected with luciferase expressing vectors 
and treated with statins show a 5 fold induction of LDLR promoter activity compared to animals no 
treated with statin. Results were obtained using live animal luciferase imaging. Figure modified from 
(Hibbitt et. al.,2010). 
Fig. 3. Genomic mini-gene vectors 
3. Conclusion  
Gene replacement gene therapy has been under investigation for a number of years and is 
emerging as a potentially potent tool to treat genetic disease.  Most gene therapy protocols 
involve the use of small cDNA vectors where expression of the transgene is constitutive and 
unregulated. While for some conditions this may be adequate, others will require the 
expression of therapeutic genes to be regulated spatially, temporally and physiologically to 
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circumvent issues with genotoxicity, loss of expression, and lack of therapeutic effect in 
animal models. 
Several advances have been made in recent years to address these issues. The use of 
transcriptional restriction is now wide-spread with many studies employing cell-specific 
promoters to ensure gene expression is limited to target cells. There have also been 
developments in the use of whole genomic DNA loci transgenes. This opens the possibility 
of using vectors for gene therapy which completely recapitulate endogenous expression. 
Advances in viral vectors based on helper virus-free HSV-1 amplicons mean that viral 
delivery of large genomic loci >100 kb  is now possible in vivo. Finally, the development of 
novel vectors which incorporate genomic DNA elements to achieve physiological 
expression in a mini-gene vector format will push the use of genomic regulatory elements in 
gene therapy vectors closer to a clinical reality. 
A greater body of work in vivo is now needed using genomic regulatory vectors. Work is 
currently underway in our laboratory to assess the feasibility of using genomic mini-gene 
vectors to correct genetic defects in vivo long-term. We believe that these vectors represent a 
major addition to the gene therapy field and will be applicable to a wide range of genetic 
conditions. 
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